SAN DIEGO--(BUSINESS WIRE)--June 5, 2006--AVANIR Pharmaceuticals (Nasdaq:AVNR - News) today announced the submission of additional data from its ongoing open label study assessing safety in chronic exposure to Neurodex(TM), an investigational new drug that is the subject of a new drug application (NDA). Neurodex is currently in priority review at the U.S. Food and Drug Administration (FDA) for the treatment of involuntary emotional expression disorder (IEED), and in Phase III clinical development as a potential treatment for painful diabetic neuropathy.
